New analysis shows survival benefit of Novartis’ Kisqali by Selina McKee | May 27, 2020 | News | 0 In patients with liver metastases, Kisqali combination therapy cut the risk of death by 47% and 37% in two trials Read More
Kisqali wins speedy US breast cancer nod by Selina McKee | Jul 19, 2018 | News | 0 Novartis’ Kisqali has been approved for breast cancer in the US less than one month after being filed with the US Food and Drug Administration. Read More